Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- DIAGNOSTIC NEWS IN BRIEF
February 4, 2002
- Gov't May Intervene If Stable Supply Is Interfered with: EAD Official
February 4, 2002
- MEDICAL DEVICE NEWS IN BRIEF
February 4, 2002
- Immediate PMS System Needs to Be Upgraded as It Is Operated
February 4, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
February 4, 2002
- 3 Companies Fail to Report Medical Device Malfunctions
February 4, 2002
- Kusuri Proverbs Reveal Japanese Spirit (2)
February 4, 2002
- 3-tierd Price Reduction Rates Set for Long-listed Drugs
January 28, 2002
- Daiichi Pharm to Acquire 100% Shares of Daiichi Fine Chemical
January 28, 2002
- Korosho Briefs Local Gov't Officials on Immediate Issues
January 28, 2002
- New Functional Classification of Medical Materials Approved as Proposed
January 28, 2002
- LDP's Subcommittee to Mull Amendment of PAL
January 28, 2002
- Sunstar Foundation to Invite Papers on Periodontal Diseases
January 28, 2002
- Gov't Panel to Monitor Life-Science-Related Projects by Different Ministries
January 28, 2002
- Eli Lilly, Vertex Select Candidate for Hepatitis C Treatment
January 28, 2002
- Serious ADR due to Topical Ketoprofen Reported
January 28, 2002
- Sanofi-Synthelabo Transfers Rights for Gabitril to Cephalon
January 28, 2002
- Results of Quality Reevaluation Announced for 20 Ingredients, 2 Formulations
January 28, 2002
- Sankyo Identifies Gene that Regulates Lipid Metabolism
January 28, 2002
- Hayashibara Strives to Be the Only 1 Rather Than No. 1
January 28, 2002
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…